303 related articles for article (PubMed ID: 15143081)
41. [Sustained long-term complete remission in an elderly aplastic anemia patient after cessation of combined therapy consisting of granulocyte-colony stimulating factor and erythropoietin].
Yasuyama M; Kawauchi K; Sugiyama H; Ohkawa S
Rinsho Ketsueki; 2000 Jan; 41(1):42-7. PubMed ID: 10695398
[TBL] [Abstract][Full Text] [Related]
42. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
43. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
44. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
45. [Clinical evaluation of recombinant human G-CSF in children with cancer].
Tsukimoto I; Hanawa Y; Takaku F; Asano S; Ueda K; Tsuchida M; Sato T; Ohira M; Hoshi Y; Nishihira K
Rinsho Ketsueki; 1990 Oct; 31(10):1647-55. PubMed ID: 1701501
[TBL] [Abstract][Full Text] [Related]
46. Shortened time to recovery from chemotherapy induced neutropenia in pediatric patients with high dose combined cytokines.
Deb G; Donfrancesco A; Sio LD; Cozza R; Castellano A; Paole F; Helson L
Anticancer Res; 1998; 18(1B):489-92. PubMed ID: 9568167
[TBL] [Abstract][Full Text] [Related]
47. A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children.
González-Vicent M; Madero L; Sevilla J; Ramirez M; Díaz MA
Bone Marrow Transplant; 2004 Dec; 34(12):1077-81. PubMed ID: 15516942
[TBL] [Abstract][Full Text] [Related]
48. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage.
Oza A; Hallemeier C; Goodnough L; Khoury H; Shenoy S; Devine S; Augustin K; Vij R; Trinkaus K; Dipersio JF; Adkins D
Transfusion; 2006 Jan; 46(1):14-23. PubMed ID: 16398726
[TBL] [Abstract][Full Text] [Related]
50. [Sequential treatment with granulocyte-colony stimulating factor (GCSF) and human recombinant erythropoietin (rH-EPO) in anemia of a patient with myelodysplastic syndrome and high blood transfusion requirements)].
Borbolla-Escoboza JR; González-Avante CM; López-Hernández MA; Flores-Chapa JD; Collados-Larumbe MT
Gac Med Mex; 1997; 133(4):355-9. PubMed ID: 9410796
[TBL] [Abstract][Full Text] [Related]
51. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation.
Pene R; Appelbaum FR; Fisher L; Lilleby K; Nemunaitis J; Storb R; Buckner CD
Bone Marrow Transplant; 1993 Mar; 11(3):219-22. PubMed ID: 8467286
[TBL] [Abstract][Full Text] [Related]
52. Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Shono Y; Morioka M; Kawamura T; Masauzi N; Kakinoki Y; Kobayashi H; Kunieda Y; Kasai M; Kurosawa M; Asaka M; Imamura M
Eur J Haematol; 2006 Nov; 77(5):403-9. PubMed ID: 16930137
[TBL] [Abstract][Full Text] [Related]
53. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
54. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
[TBL] [Abstract][Full Text] [Related]
55. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.
Olivieri A; Scortechini I; Capelli D; Montanari M; Lucesole M; Gini G; Troiani M; Offidani M; Poloni A; Masia MC; Raggetti GM; Leoni P
Bone Marrow Transplant; 2004 Oct; 34(8):693-702. PubMed ID: 15300235
[TBL] [Abstract][Full Text] [Related]
56. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
57. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
Kavgaci H; Ozdemir F; Aydin F; Yavuz A; Yavuz M
J Exp Clin Cancer Res; 2002 Dec; 21(4):475-9. PubMed ID: 12636092
[TBL] [Abstract][Full Text] [Related]
58. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Chao NJ; Schriber JR; Long GD; Negrin RS; Catolico M; Brown BW; Miller LL; Blume KG
Blood; 1994 May; 83(10):2823-8. PubMed ID: 7514046
[TBL] [Abstract][Full Text] [Related]
59. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock.
Stephens DP; Thomas JH; Higgins A; Bailey M; Anstey NM; Currie BJ; Cheng AC
Crit Care Med; 2008 Feb; 36(2):448-54. PubMed ID: 18216600
[TBL] [Abstract][Full Text] [Related]
60. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
